1001353-87-2

Usage

Uses

Used in Pharmaceutical Industry:
(S)-1-(tert-Butoxycarbonyl)-4,4-dimethylpyrrolidine-2-carboxylic acid is used as a protecting group for acid-sensitive amines in the synthesis of pharmaceutical compounds. Its Boc group helps prevent unwanted reactions at specific positions on a molecule, ensuring the desired product is obtained.
(S)-1-(tert-Butoxycarbonyl)-4,4-dimethylpyrrolidine-2-carboxylic acid is also used as a chiral auxiliary in asymmetric synthesis. Its presence aids in the selective formation of enantiomers, which is crucial for the development of drugs with desired biological activities and reduced side effects.
Furthermore, (S)-1-(tert-Butoxycarbonyl)-4,4-dimethylpyrrolidine-2-carboxylic acid is utilized in the production of drugs and pharmaceutical intermediates. Its versatile structure and functional groups make it a valuable component in the synthesis of various therapeutic agents, contributing to the advancement of medicinal chemistry.

Upstream product

• 1001353-86-1 (S)-4,4-dimethylpyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester 
• 158392-74-6 O₁-tert-butyl O₂-methyl (2S)-4,4-dimethyl-5-oxopyrrolidine-1,2-dicarboxylate 
• 138423-86-6 Methyl (2S)-1-(tert-bytoxycarbonyl)-4,4-dimethylprolinate 
• 7149-65-7 ethyl (S)-pyroglutamate 
• 144978-35-8 (S)-ethyl N-tert-butoxycarbonylpyroglutamate 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 891183-50-9 4,4-dimethyl-L-proline 
• 1613055-96-1 C₂₀H₂₆BrN₃O₂ 
• 1613055-97-2 C₂₆H₃₈BN₃O₄ 
• 1613055-98-3 C₃₂H₃₆F₃N₃O₅S 
• 212890-86-3 (S)-(-)-tert-butyl 2-(hydroxymethyl)-4,4-dimethylpyrrolidinecarboxylate 
• 1262400-68-9 (S)-4,4-Dimethyl-pyrrolidine-2-carboxylic acid methyl ester; hydrochloride 
• 1613055-95-0 C₂₀H₂₆BrNO₅ 

Relevant academic research and scientific papers

As hepatitis c inhibitor spiro compound and its use in medicine

The invention provides a spiro compound serving as a hepatitis c inhibitor and application thereof in a medicine. The compound is a compound as shown in a formula (I) or a stereisomer, a geometric isomer, a tautomer, nitric oxide, an aquo-complex, a solvate, a metabolite, pharmaceutically acceptable salt or prodrug of the compound as shown in the formula (I). The invention also provides a pharmaceutical composition containing the compound, application of the compound and the pharmaceutical composition in inhibition of HCV (Hepatitis C Virus) copy and HCV virus protein, as well as the application of the compound and the pharmaceutical composition in prevention, handling, treatment or relieving of HCV infection or hepatitis c disease for a patient. The formula I is as shown in the specification.

FUSED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided are fused tricyclic compounds effective to inhibit the function of the NS5A protein of formula (I), wherein X, X', Y, Y', A, A',Q1, Q2, R1-R4, X4, R5a, f and W are defined as in the description. Also provided herein are pharmaceutical compositions thereof, and uses in the manufacture of a medicament for treating HCV infection or a HCV disorder thereof.

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds

PYRROLOTRIAZINE KINASE INHIBITORS

The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.